Poliomyelitis Market

Market Overview:

The 7 major poliomyelitis markets are expected to exhibit a CAGR of 5.04% during 2024-2034.

The poliomyelitis market has been comprehensively analyzed in IMARC's new report titled "Poliomyelitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Poliomyelitis, commonly known as polio, refers to a highly infectious viral disease caused by the poliovirus. It primarily affects young children, but people of all ages can be impacted. Most individuals infected with the poliovirus experience no symptoms or only mild flu-like indications. However, in a small percentage of cases, the virus invades the nervous system, leading to more severe symptoms. This form of polio is characterized by muscle weakness or paralysis, often asymmetrically affecting the limbs. Various other indications may include loss of reflexes, muscle pain, fatigue, headache, fever, stiffness in the neck and back, etc. In rare cases, the virus can affect the muscles involved in breathing, potentially leading to respiratory distress or failure. Diagnosing poliomyelitis typically consists of a combination of clinical evaluation, laboratory testing, and epidemiological investigation. Initially, a healthcare professional will assess the patient's symptoms, medical history, and potential exposure to the poliovirus. A physical examination may reveal muscle weakness, decreased reflexes, or abnormal sensations. Several laboratory tests, such as viral culture or polymerase chain reaction (PCR), are used to detect the presence of the poliovirus in throat swabs, stool samples, or cerebrospinal fluid.

The increasing cases of poor sanitation, inadequate hygiene practices, and close personal contact, which can contribute to the transmission of the poliovirus, are primarily driving the poliomyelitis market. Moreover, the widespread adoption of non-opioid analgesics, such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), for reducing inflammation as well as relieving pain in patients without the risk of opioid-related side effects or dependency is further bolstering the market growth. Apart from this, the inflating application of various assistive devices, including braces, orthotics, canes, crutches, wheelchairs, etc., for enhancing mobility and independence for individuals suffering from polio is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of complementary therapies, such as acupuncture, acupressure, massage therapy, etc., since they can help to promote relaxation, improve blood circulation, and decrease muscle tension, is creating a positive outlook for the market. Additionally, the introduction of new vaccine formulations, including the inactivated polio vaccine (IPV) and the novel oral polio vaccine (nOPV), which aid in reducing the risk of vaccine-associated paralytic polio while maintaining high immunogenicity, is expected to drive the poliomyelitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the poliomyelitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for poliomyelitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the poliomyelitis market in any manner.

IMARC Group's new report provides an exhaustive analysis of the poliomyelitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for poliomyelitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the poliomyelitis market in any manner.

Key Highlights:

• Polio (poliomyelitis) typically affects children under the age of five.
• In the twentieth century, approximately 16,000 cases of polio (paralytic poliomyelitis) were reported annually in the United States, compared to zero in 2020.
• Poliovirus type 1 has historically been the most common cause of poliomyelitis worldwide and continues to be spread in endemic areas.
• The majority of poliovirus infections are observed to be asymptomatic; up to 70% of infected persons suffer no symptoms, while approximately 25% experience mild symptoms.
• Paralytic poliomyelitis accounts for less than one percent of all infections.
• The fatality rate for acute paralytic polio is between 5 and 15%.

Drugs:

Pediarix is a combination product containing hepatitis B, DTaP, and inactivated polio vaccines. It is manufactured by GlaxoSmithKline. Pediarix is approved for a three-dose main series at 2, 4, as well as 6 months of age. It is licensed for children from six weeks to six years.

VAXELIS refers to a vaccine indicated for active immunization to prevent poliomyelitis and invasive disease due to Haemophilus influenzae type b. VAXELIS has been authorized for usage as a three-dose series for children aged six weeks to four years. The three-dose immunization regimen includes a 0.5 mL intramuscular injection given at 2, 4, and 6 months of age.

Quadracel is a vaccine used for active vaccination against diphtheria, tetanus, pertussis, and poliomyelitis. Quadracel is approved as a fifth dose in diphtheria, tetanus, and pertussis (DTaP) vaccination series, as well as a fourth or fifth dose in the inactivated poliovirus (IPV) vaccination series, in children aged four to six years who have previously received DTaP vaccine doses with Pentacel, DAPTACEL, and/or VAXELIS.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the poliomyelitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the poliomyelitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current poliomyelitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the poliomyelitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the poliomyelitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the poliomyelitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of poliomyelitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of poliomyelitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of poliomyelitis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with poliomyelitis across the seven major markets?
• What is the size of the poliomyelitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of poliomyelitis?
• What will be the growth rate of patients across the seven major markets?
   

Poliomyelitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for poliomyelitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the poliomyelitis market?
• What are the key regulatory events related to the poliomyelitis market?
• What is the structure of clinical trial landscape by status related to the poliomyelitis market?
• What is the structure of clinical trial landscape by phase related to the poliomyelitis market?
• What is the structure of clinical trial landscape by route of administration related to the poliomyelitis market?